Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash & Equivalents: 2019-2025

Historic Revenue - Interest and Investment Income for Legend Biotech (LEGN) over the last 1 years, with Sep 2025 value amounting to $1.7 billion.

  • Legend Biotech's Revenue - Interest and Investment Income rose 3495912.24% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 144628.17%. This contributed to the annual value of -$278,000 for FY2020, which is N/A change from last year.
  • As of Q3 2025, Legend Biotech's Cash & Equivalents stood at $278.9 million, which was up 4.62% from $266.6 million recorded in Q2 2025.
  • Legend Biotech's 5-year Cash & Equivalents high stood at $1.3 billion for Q4 2023, and its period low was $379,776 during Q2 2022.
  • For the 3-year period, Legend Biotech's Cash & Equivalents averaged around $633.3 million, with its median value being $459.3 million (2024).
  • The largest annual percentage gain for Legend Biotech's Revenue - Interest and Investment Income in the last 5 years was 3,495,912.24% (2025), contrasted with its biggest fall of 185,638.67% (2025).
  • Over the past 2 years, Legend Biotech's Revenue - Interest and Investment Income (Quarterly) stood at $1.7 billion in 2024, then spiked by 3,495,912.24% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q3 2025, -$1.7 billion for Q2 2025, and $1.7 billion during Q4 2024.